Beijing Mabworks Biotech Co., Ltd. Sustainability Profile
Beijing Mabworks Biotech Co., Ltd., commonly referred to as Mabworks, is a leading player in the biopharmaceutical industry, headquartered in Beijing, China. Founded in 2010, the company has rapidly established itself as a pioneer in the development of monoclonal antibodies and innovative therapeutic solutions, catering to both domestic and international markets. Mabworks focuses on the research, development, and production of high-quality biopharmaceuticals, with a particular emphasis on oncology and autoimmune diseases. Their unique approach combines advanced technology with a commitment to quality, setting them apart in a competitive landscape. Notable achievements include successful collaborations with global pharmaceutical companies and a robust pipeline of proprietary products, solidifying Mabworks' position as a trusted name in biotechnology.
DitchCarbon Score
How does Beijing Mabworks Biotech Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Beijing Mabworks Biotech Co., Ltd.'s score of 0 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Beijing Mabworks Biotech Co., Ltd.'s reported carbon emissions
Beijing Mabworks Biotech Co., Ltd., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, the company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to mitigate carbon emissions at this time. As there are no emissions data or reduction initiatives available, it is essential to note that the company may still be in the early stages of developing its climate strategy. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon neutrality, often setting ambitious targets in line with global climate agreements. However, without specific commitments or data, it is unclear how Beijing Mabworks Biotech Co., Ltd. aligns with these industry trends.
How Carbon Intensive is Beijing Mabworks Biotech Co., Ltd.'s Industry?
How Carbon Intensive is Beijing Mabworks Biotech Co., Ltd.'s Location?
Beijing Mabworks Biotech Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Beijing Mabworks Biotech Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
